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Abstract The fraction of the emitted dose from an inhaler that has the potential to be deposited into the lungs is
known as the fine particle dose (also the respirable dose).During inhalation all dry powder inhalers require a ‘force’to
be created inside the device so that a fine particle dose is generated fromthe formulation in themetering chamber.This
‘force’is formedby the inhalationrate used togetherwiththeresistance (andhence design) inside aninhaler.Studieshave
shown that the fine particle dose is related to the clinical effect whilst other studies have reported that this dose can
be dependent on the inhalation rate used.The inhalation technique recommended by the manufacturer of an inhaled
device should, therefore, be used. For those dry powder inhalers that demonstrate significant flow dependent dosage
emissionitisimportantthatpatientsusethemostdesirableratethathasbeenreported.The In-CheckDialis a simple and
ease to use meter that can be used to measure the inhalation rate of a patient when they use each of the commonly
prescribed inhalers that are currently available.This meter can be used to identify the most suitable inhaler for each
individual. r2002 Publishedby Elsevier Science Ltd.
Available online athttp://www.sciencedirect.com
Keywords dry powder inhaler; inhalation rates; in-check dial.To ensure e¡ective and consistent management of
asthma orchronic obstructivepulmonarydisease, it is es-
sential that patients are compliant and that they can use
their inhaled medication according to the instructions
provided by the manufacturers. For the latter, it may be
necessary to train the patient with the required inhala-
tion technique for the inhaler they have been prescribed.
However, studies have shown that although training en-
ables the correct technique to be used these improve-
ments for both metered dose inhalers (MDIs) (1,2) and
dry powder inhalers (DPIs) (3) are only temporary.
Although the MDI is the most commonly prescribed
device patients have problems with co-ordinating the
start of inhalation with actuating a device (4,5).Co-ordi-
nation problems can be overcome by either attaching a
spacer or a breath-actuated MDI. The inhalation used
with a MDI should not be too fast otherwise central de-
position in the large airways will predominate (6). All
DPIs are breath actuated, but each type of device re-
quires a di¡erent technique together with a disparate
method of preparing a dose for inhalation.
There are many types of DPIs and each is designed to
emit a consistent dose over a speci¢c range of inhalationReceived14 January 2002, accepted in revised form17 January 2002.
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1274 236 490; E-mail: h.chrystyn@bradford.ac.ukrates.To identify the patient’s inhalation rate through an
inhaler, and therefore the device to suit a patient’s natur-
al technique, the In-Check Dial (Clement Clarke Inter-
national) has been introduced. Use of this device in the
Clinic should enable the prescriber to choose an inhaled
device that requires minimal training of the recom-
mended inhalation technique.
Figure1 shows that the In-Check Dial is similar in ap-
pearance to a peak £owmeter.The di¡erence is that in-
halation is used rather than a forced expiration.The rate
of inhalation ismeasuredbyreading thevalue on theme-
ter (analogous to that of the measured peak £ow). The
In-Check Dial is designed to mimic the use of a speci¢c
inhaled device. Each setting on the dial corresponds to a
di¡erent type of inhaler (e.g. AutohalerF3MHealthcare
Ltd, ClickhalerFMedeva Pharma Ltd, Diskus, known
in the U.K. as the AccuhalerFGlaxoSmithKilne, Easi-
BreatheFNorton Healthcare, andTurbuhalerFAstra-
Zeneca). When the patient inhales through the
In-Check Dial, the reading provides the inhalation rate
thatwouldbe obtainedwhenusing the inhaler for which
themeter has been set for.
Respirable dose emitted froman inhaler
The recommended inhalation technique for each DPI de-
vice ensures that a dose of particleswith the potential of
FIG 1. The In-Chek Dial.
FIG. 2. The process of generatinga respirable dose froma formulation ofmicronised drugand lactose in a DPI.
182 RESPIRATORYMEDICINEdeposition into the airways is created during each inhala-
tion. Particles between1and 5mmhave the greatest po-
tential to deposit in the lungs, during an inhalation (7),
with an even distribution throughout the airways (8).
This fraction of the emitted dose from an inhaler is
termed the respirable dose (also ¢ne particle dose or re-
spirable fraction).
During manufacture and dose metering it is essential
that the powder has consistent, smooth £ow. However,
particles smaller than 5mmdo nothave these £owprop-
erties and thus modi¢cations to the formulation are re-
quired.Two di¡erent principles are used to improve £ow.
The most common is to mix the drug particles with an
inert carrier whose particles are larger.The most com-
mon carrier is lactose. The two powders are mixed to-
gether and the adhesion of the drug to the carrier is
such that there is no separation.During inhalation there
has to be a break of this weak bond between the drug
and its carrier to generate the respirable dose. This
break is causedby the generation of ‘force’within thede-
vice during inhalation. This ‘force’ is created from a pa-
tient’s inhalation by resistance in the device as shown in
Fig. 2.The other method used to improve £ow is to for-mulate the drug into spheres (e.g.Turbuhaler).During in-
halation ‘force’ is required to generate a respirable dose.
Like the lactose formulations this ‘force’ is created from
the patient’s inhalation rate by resistance inside the de-
vice to ensure that turbulence of air£ow is created to
break up the spheres into particles of the required re-
sprable size.
The design of each type of DPI is optimised to emit
their formulation as a respirable dose during inhalation.
Due to di¡erent formulations the resistance in each type
of DPI is di¡erent. Inhalation rate is very important to
generate the respirable dose from aDPI. All patientswill
inhale at a di¡erentrate and thus the design and formula-
tion of each inhaler should be such that the most desir-
able range of inhalation rates required is achievable by all
patients, of all ages and at all times.
Studies have shown that the dose emitted from some
DPIs is dependenton £ow (9^11).These are in vitro studies
that also highlight that for some DPI devices there is a
large variability in the emitted dose at a set inhalation
rate. These in vitro properties of £ow-dependent dose
emission are, however, insigni¢cant if they are not clini-
cally relevant.
FIG. 3. The ratio for the change in the number of logarithmic
doubling concentrations of histamine to reduce the FEV1by 20%
(PC20 [FEV1]) between inhalation of budesonide through a MDI
and Turbuhaler plotted against the inhalation rate usedwith the
Turbuhaler by 25 asthmatics. Reproduced with permission of
Munksguard International Publishers Ltd (Copenhagen, Den-
mark) fromEngeletal.Clinicalcomparisonof inhaledbudesonide
delivered via pressurizedmetered dose inhaler orTurbuhalers.
Allergy1989; 44: 220^225.
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Bronchodilators
It has been reported that the total dose deposited into
the lungs is more important than regional distribution
(8). An analysis of studies investigating lung deposition
using gamma scintigraphy has shown that there is a sig-
ni¢cant correlation between the total lung dose and the
¢ne particle dose (12). Similar relationships have been
shown using urinary pharmacokinetic methods designed
to identify total lung deposition (13,14).The clinical rele-
vance of di¡erent lung deposition is di⁄cult to apply to
an inhaledbronchodilatordrug.Urinarypharmacokinetic
studies have shown that theTurbuhaler deposits twice as
much drug into the lungs than the equivalentdose from a
MDI (15). Spirometry in this study only revealed a di¡er-
ence for the lower dose inhaled from the MDI.This pro-
blem of doses at the top of the dose response curve is
highlighted by a study, which showed that although lung
deposition from an MDI and MDI attached to a spacer
was12.3 and 23.5%, respectively, therewas no di¡erence
in spirometry (16). In another study, no di¡erence in
spirometrymeasurementswere found following cumula-
tive doses from a MDI and Turbuhaler (17). However, si-
multaneous measurement of heart rate did highlight the
greater emitted dose from theTurbuhaler. Similar indir-
ect indications of £ow-dependent dose emission from a
Turbuhaler were reported in a study by Engel et al. (18).
Following inhalation of terbutaline from a Turbuhaler
using rates of 34 and 84 lmin1, the change in FEV1was
8 and 11.5%, respectively, whereas in vitro measurement
of the emitted dosewasmuch greater at the higher £ow
rate. This suggests that the spirometry measurements
were at the top of the dose response relationship. The
di¡erence in the emitted dose was highlighted by signi¢-
cantly (Po0.01) lower plasma terbutaline concentrations
for the inhalation at 34 lmin1.
The confusion frommeasurements at the top of dose
responserelationshipswith therapeutic doses of bronch-
odilators and thus the di⁄culty to demonstrate the clin-
ical relevance of £ow-dependent dose emission has been
further demonstrated in children (19). Inhalations below
30 lmin1 demonstrated a dose response relationship,
but therewas no di¡erence above 30 lmin1. Although a
much larger dose inhaled at each £ow rate later in the
study day did show equal (and greater) bronchodilation,
this was given when the airways had been previously di-
lated 6h earlier, and was also inhaled at a di¡erent time
of the day. A link between better clinical response, in-
spiratory capacity anddose emission from theTurbuhaler
was demonstrated by Hirsch et al. (20). They reported
that the children with higher inspiratory capacity ob-
tained an improvedbronchodilatorye¡ect. A further re-
port, in abstract form, has also highlighted the
relationship between inhalation rate through theTurbu-
haler and response (21).Corticosteroids
For corticosteroids, the measurement of spirometry is
more of a problem in that a doubling of the steroid dose
has been shown to increase the peak expiratory £ow by
only 4.3 lmin1(22). Bronchprovocation is, therefore,
more appropriate.Figure 3 shows that there is a clear re-
lationship between the dose of histamine to reduce the
FEV1by 20% and the peak inspiratory £ow through aTur-
buhaler containing budesonide (23).
The data presented in Fig. 3 are consistent with gam-
ma scintigraphy studieswhichhighlightgreater total lung
deposition following inhalation of budesonide from aTur-
buhaler using rates of 36 and 58 lmin1 (24). The mean
(SD) total lung deposition was 14.8 (3.3) and 27.7 (9.5)%,
respectively (24). Using terbutaline inhaled at 28 and
57 lmin1 through a Turbuhaler, another gamma scinti-
graphy study has demonstrated that the total lung de-
position was 9.1 (1.5) and 16.8 (2.6)%, respectively (21).
The data are consistent with the published comments
that for theTubuhaler device ‘a direct relationship exists
between peak inspiratory £ow and lung deposition’ (24)
and that 60 lmin1 ‘was the optimal inhalation rate for
use through the Turbuhaler’ (15,25). The lungs are the
onlyroute for the systemic deliveryof £uticasone follow-
ing inhalation.Measurement of the area under the curve
from plasma £uticasone concentrations in12 children in-
jaling £uticasone from aDiskus at inhalation £owrates of
35^74 lmin1 showed no di¡erence (26). Thus, for the
Diskus there is no e¡ect due to inhalation rate which is
consistent with the reported in vitro data (9^11).
FIG. 4. The intra-individual variabilityof10 patientswhenthey
inhaleusingaDiskusandTubuhaler.Reproducedwithpermission
ofthe BMJPublishing Group fromTarsin et al.The intra-individual
variability of inhalation rates through two di¡erentdry powder
inhalers.Thorax 2000; 55 (Suppl 3): A61.
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In vitro studies using the I.S.F device (also known as the
Cyclohaler and currently the AerolizerFNovartis Phar-
maceuticals) have demonstrated £ow-dependent dose
emission (27,28). An in vivo study has con¢rmed this phe-
nomenon for the Aerolizer (29). Following inhalation of
12mg of eformoterol, from an Aerolizer, the protective
e¡ect on the FEV1 following exercise at 12h post dose
wasmeasured in16 children aged 8^15 years. After a pla-
cebo dose, the FEV1 decreased by 34% after exercise,
whilst after inhalation using a high £ow rate it decreased
by 15% compared to 23%, when a lower £ow rate had
been used.
In vitro studies have shown that other DPIs emit a dose
which is independent of £ow (9^11,27,28).The Diskus has
demonstrated such a property (9^11), and a clinical study
(30) using salmeterol through this device has shown
no di¡erence in the FEV1 12h post exercise when the
dose was inhaled by children at £ow rates of 30 and
90 lmin1.
For some dry powder devices, low £owrates
are slightly better than fast ones
In vitro (31,32) and clinical (33) studies using the Clickhaler
together with lung deposition using gamma scintigraphy
(34) and urinary pharmacokinetics methods (35) have
shown that inhalation £ow rate is a minor issue for this
devicewithmarginally better performance at lower £ow
rates. The results revealed that for salbutamol (31) and
beclomethasone (32), the delivered dose was consistent
over the range of inhalation rates routinely achieved by
patients (35). A randomised, double-blind, placebo-con-
trolled comparison of salbutamol inhaled, from a Clic-
khaler at 15, 30 and 60 lmin1 by 16 patients with stable
asthma showed no di¡erence in the bronchodilator re-
sponse (33).Correlation of the in vitro (31,32) and clinical
data (33) was strengthened by demonstration of similar
relative lung deposition for salbutamol (35) although this
index was slightly higher at 30 lmin1compared to inha-
lation at 60 lmin1.This latter study highlights the link to
and importance of the respirable dose (35) The formula-
tion with a high respirable dose provided a greater rela-
tive lung bioavailability than that with the low respirable
dose formulationwhen inhaled at 30 and at 60 lmin1. A
comparison of the total lung deposition of radiolabelled
beclomethasone inhaled from a Clickhaler showed that
higher lung deposition was obtained at the lower £ow
rate (34).This study also revealed that the higher inspira-
tory £owrates through theDPI tended to result in great-
er central deposition.
Better lung deposition at a lower inhalation rate for a
DPI has also been reported for the Spiros Inhaler (Dura
Pharmaceuticals, U.S.A). At 60 lmin1 compared to
15 lmin1, themean (SD) total lung deposition for salbuta-mol was 19.3 (7.3) and 25.8 (9.2)%, respectively (36). For
radiolabelled beclomethasone, in this device, the higher
lung deposition at the lower inspiratory £ow rate was
accompanied by lower oropharyngeal deposition (37).
Inhalation rates by patients
Studies have shown (38^40) that the Rotahaler (GlaxoS-
mithKline) and Spinhaler(Rhone Poulenc Rorer) have a
low resistance, whilst, the Diskhaler (GlaxoSmithKline)
and Diskus together with the Aerolizer have a medium
resistance, whereas the Clickhaler, Turbuhaler and an
Easyhaler (Orion Pharma) together with a placebo ver-
sion of theTwisthaler (Schering Plough) all have a high re-
sistance. Studies have shown that there is a large inter-
patient variability of inhalation rates when patients use
a Diskus (41,42), Turbuhaler (41^44), Clickhaler (35,41)
and Easyhaler (41,45).
Patients with COPD have been reported to have low-
er inhalation rates than adult asthmatics (41).This study
also showed that asthmatic children (aged 5^16 years)
achieved the highest inhalation rates, and that the more
severe the restriction the lower were the inhalation
rates through a variety of inhalers (41). Some studies
(19,43) have recommended that the Turbuhaler device
was not suitable for pre-school children because of the
low £ow achieved by this group. It has also been shown
that the inhalation rates achieved by some patients (40)
mirrors that of the resistance within each DPI device.
Furthermore, Fig.4 shows that there is a considerable in-
tra-patient variability of inhalation rates when patients
inhale through a Diskus (Accuhaler) and a Turbuhaler
(46).
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Integration of all the above data highlights that there is a
link between the emitted dose (in particular the respir-
able dose), total lungdeposition andultimatelyclinical re-
sponse.The data also indicate that there is a di¡erence in
the emitted dose from DPIs with respect to the inhala-
tion rate used and that for some devices this di¡erence
is clinically signi¢cant. Manufacturers should, therefore,
be encouraged to label their product with the dose
emitted at di¡erent £ow rates. Intra- (46) and inter- (41)
patient variability and a decreased inspiratory e¡ort due
to deterioration (47)maygive rise to inconsistentdosing.
Although the patient can compensate these inconsisten-
cies when using their bronchodilator by titrating their
dose with subjective response this cannot be applied to
the corticosteroids.
Themostdesirable inhaler to prescribe for a patient is
dependent on many factors. Asking the patient which
they prefer is part of the process, but previously there
has been no simplemethod of determining if the patient
can use the chosen inhaler.The data above highlights the
increased awareness of the role of inspiratory £owmea-
surement as a tool in inhaler device selection (48). Some
manufacturers have produced a peak inhalation rateme-
ter for their own inhaler.The In-Check Dial has recently
been introduced and contains the option to measure in-
halation rates for a variety of inhalers. Studies have high-
lighted the potential of this meter to identify the
inhalation rate, and thus inspiratory e¡ort, of all types
of patients using di¡erent DPIs (41,49^52). In these studies,
the In-Check Device has shown that only six (8%) out of
74 COPD patients (49) together with 48 (51) and 17 (52)
children out of 64 (75%) and 57(30%), respectively, could
generate an inspiratory £ow of4 60 lmin1when using
theTurbuhaler. For theTurbuhaler device, it has been re-
ported that460 lmin1 is the most desirable rate (24)
and in vitro studies (9^11) have highlighted high variability
of the emitted dose below this inhalation rate.However,
it can be argued that some clinical response is obtained
between 30 and 60 lmin1, through this device (19), but
the clinical e¡ect of the intra-individual variability of in-
halationrates (46) is notknown.Using the In-CheckDial,
14 out of 74 (19%) COPD patients (49) and three out of19
(16%) asthamatics (19), could not generate the minimum
(30 lmin1) inhalation rate required for the Tubuhaler.
Only19 out of 64 (30%) children could achieve the most
desirable inhalation rate for the Aerolizer (51).
The inhalation rates obtained by 25 COPD patients
when the In-CheckDialwas set for anAerolizer, Diskus,
Turbuhaler,Clickhaler, placeboTwisthaler and an Easyha-
ler were all in the same order as the internalresistance in
each device (40). Signi¢cant (Po0.01) correlations (46)
have been found between the peak inhalation rate mea-
sured electronically, during characterisation of the in-
spiratory pro¢le, and the In-Check Dial when patientsinhaled through a Diskus and Turbuhaler. Thus, the In-
Check Dial is an accurate method to identify inhalation
rates and has been externally tested by AEATechnology
(53). The initial velocity during an inhalation through a
drypowder device hasbeen reported to be themain fac-
tor which determines the respirable dose (54,55).
Although the In-check Dial does not measure this para-
meter, a recent study has shown a correlation between
the initial velocity when a patient uses an inhaler and the
measured peak inhalation rate (56).
Although the emphasis for using the In-Check Dial is
for DPIs, it also has the ability to measure the peak inha-
lation rate when there is no resistance to an inhalation.
Thus, the patient’s inhalation rate through aMDI orwhen
it is attached to a spacer can be measured. If these rates
are too high, then total lung depositionwill be decreased
and be concentrated in the central zones of the lungs
(6,57). If thesepatients cannot slowdown their inhalation
rate, then a devicewith some resistance can be chosen.
Training inhaler technique is time consuming, thus is a
cost issue, and studies have shown that forMDIs (1,2) and
DPIs (3) patients revert back to their original technique.
In the clinic, the In-Check Dial can be used to identify an
inhaler they can use without training. Since there is an
intra-patient variability of peak inhalation rates (46), a
measurement in the middle of the most desirable range
for an inhaler should be used.Of those which the meter
identi¢es as suitable the patient can be asked to select
which they would prefer.The patient can then be asked
to inhale a dose through a placeboversion, of this inhaler,
without instruction. If the patient gets this last step cor-
rect, then the optimal inhaler is identi¢edandno training
on how to use it correctly should be necessary.
REFERENCES
1. Paterson IC, Crompton GK. Use of pressurised aerosols by
asthmatic patients. Br Med J 1976 1: 76–77.
2. Crompton GK. Problems patients have using pressurised aerosol
inhalers. Eur J Respir Dis 1982; 119: (Suppl) 101–104.
3. Nimmo CJ, Chen DN, Martinusen SM, Ustad TL, Ostrow DN.
Assessment of patient acceptance and inhalation technique of a
pressurized aerosol inhaler and two breath-activated devices. Ann
Pharmacother 1993; 27: 922–927.
4. Larsen JS, Hahn M, Ekholm B, Wick KA. Evaluation of conventional
press-and-breathe metered-dose inhaler technique in 501 patients.
J Asthma 1994; 31: 193–199.
5. Erickson SR, Horton A, Kirking DM. Assessing metered-dose
inhaler technique: Comparison of observation v’s patient self
report. J Asthma 1998; 35: 575–583.
6. Newman S, Steed K, Hopper G, Kallen A, Borgstrom L.
Comparison of gamma scintigraphy and a pharmcokinetic
technique for assessing pulmonary deposition of terbutaline
sulphate delivered by pressurized metered dose inhaler. Pharm
Res 1995; 12: 231–236.
7. Chrystyn H. Anatomy and physiology in delivery: can we define
our targets. Allergy 1999; 54: 82–87.
8. Chrystyn H Is total particle dose more important than particle
distibution. Respir Med 1997; 91 (Suppl. A): 17–19.
186 RESPIRATORYMEDICINE9. Palander A, Mattila T, Karhu M, Muttonen E. In-vitro comparison of
three salbutamol-containing multidose dry powder inhalers. Clin
Drug Invest 2000; 20: 25–33.
10. Malton A, Sumby BS, Smith IJ. A comparison of in-vito drug delivery
from tow multidose powder inhalation devices. Eur JClin Res 1995:
7: 177–193.
11. Malton A, Sumby BS, Dandiker Y. A comparison of in-vito drug
delivery from salbutamol Diskus and terbutaline Turbuhaler
inhalers. J PharmMed 1996; 6: 35–45.
12. Barry PW. Problems with inhalation drug delivery. PhD Thesis.
University of Leicester, Leicester, 1999: 118–130.
13. Olsson B, Asking L, Borgstrom L, Bondesson F. Effect of inlet
throat on the correlation between the fine particle dose and lung
deposition. In: Dalby RN, Bryon PR, Farr SY (eds). RespiratoryDrug
Delivery, Vol. V. USA: Interpharm Press Inc. 1996; 273–281.
14. Sikstone VL, Dennis JH, Pieron CA, Chrystyn H. An investigation
of in-vitro/in-vivo correlations for salbutamol nebulized by eight
systems. J Aerosol Med 2002 (in press).
15. Borgstrom L, Derom E, Stahl E, Wahlin-Boll E, Pauwels R. The
inhalation device influences lung deposition. Am J Respir Crit Care
Med 1996; 153: 1636–1640.
16. Newman SP, Talaee N, Clarke SW. Salbutamol aerosol delivery in
man with the Rondo Spacer. ActaTher 1991, 17: 49–50.
17. Johnsen CR, Weeke ER. Turbuhaler F a new device for dry
powder terbutaline inhalation. Allergy 1988; 43: 392–395.
18. Engel T, Scharling B, Skovsted B, Heinig JH. Effects, side effects and
plasma concentration of terbutaline in adult asthmatics after
inhaling from a dry powder inhaler device at different flows and
volumes. Br J Clin Pharmacol 1992; 33: 439–444.
19. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow-
rate upon the effect of a Turbuhaler. Arch Dis Child 1990; 65:
308–310.
20. Hirsch T, Peter-Kern M, Koch R, Leupold W. Influence of
inspiratory capacity on brochodilation of terbutaline via turbu-
halers or pressurised metered-dose inhaler in asthmatic children:
a comparison. Respir Med 1997; 91: 341–346.
21. Dolovich M, Vanzieleghem M, Hidinger K-G, Newhouse M.
Influence of inspiratory flow rate (Vi) on the response to
terbutaline (T) inhaled via the Turbuhaler (TH) Allergy Proc.
1988; 9: 380.
22. Dahl R, Lundback B, Malo JL MD, Mazza JA, Nieminen MM,
Saarelainen P, Barnacle H. A dose ranging study of fluticasone
propionate in adult patients with moderate asthma. Chest 1993;
104: 1352–1358.
23. Engel T, Heinig JH, Malling H-J, Scharling B, Nikander K, Madesen
F, Clinical comparison of inhaled budesonide delivered either via
pressurized metered dose inhaler or Turbuhalers. Allergy 1989;
44: 220–225.
24. Borgstrom L, Bondesson E, Moren F, Trofust E, Newman SP. Lung
deposition of budesonide inhaled via TurbujalersF a comparison
with terbutaline sulfate in normal subjects. Eur Respir J 1994; 7:
69–73.
25. Agertoft L, Pedersen S. Influence of inspiratory flow rate on plasma
levels and lung deposition of fluticasone properties inhaled from
Diskus Dry Powder Inhaler. Eur Respir J 1999; 14 (Suppl. 30): 1264
26. Nielsen KG, Skov M, Klug B, Ifversen M, Bisgaard H. Flow-
dependent effect of formoterol dry-powder inhaled from an
Aerolizer. Eur Respir J 1997; 10: 2105–2109.
27. Newman SP, Moren F, Trofast E, Talaee N, Clarke SW.
Terbutaline sulfate Turbuhaler F effect of inhaled flow-rate on
drug deposition and efficacy. Int j Pharm 1991; 74: 209–213.
28. Steckel H, Muller BW. In-vitro evaluation of dry powder inhalers I:
drug deposition of commonly used devices. Int J Pharm 1997; 154:
19–29.
29. Srichana T, martin GP, Marriott C, Dry powder inhalers.
The influence of device resistance and powder formulationon drug and lactose deposition in vitro. Eur j pharm Sci 1998; 7:
73–80.
30. Nielsen KG, Auk IL, Bojsen K, Ifversen M, Klug B, Bisgaard H.
Clinical effect of Diskus dry-powder inhaler at low and high
inspiratory flow-rates in asthmatic children. Eur Respir J 1998; 11:
350–354.
31. Barrowcliffe j, McGlynn P, Tickle S, Sandbank F, Wong T. The in-
vitro evaluation of a novel multi-dose dry powder inhaler. In:
The Aerosol Society (eds), Drug Delivery to the Lungs, Vol. VII. The
Aerosol Society, Bristol. December 1996: 82–85.
32. Barrowcliffe J, McGlynn, Ratcliffe S, Sewell M, Sheikh S. Walters M.
Beclomethasone dispropionate (BDP) ClickhalerTM. In vitro perfor-
mance of a sterod novel dry powder inhaler. In: The Aerosol
Society (eds), Drug Delivery to the Lungs, Vol. VIII. The Aerosol
Society, Bristol. December 1997: 125–128.
33. Newhouse MT, Nantel MP, Chambers CB, Pratt B, Parry-Bilings M.
Clickhaler (a novel dry powder inhaler) providing similar
brochodilation to pressurized metered dose inhaler, even at low
flow rates. Chest 1999; 115: 952–956.
34. Warren SJ, Taylor G. Effect of inhalation flow profiles on the
deposition of radiolabelled BDP from a novel dry powder inhaler
(DPI, ClickhalerTM), a conventional metered dose inhaler (MDI)
and MDI plus spacer. In: Dalby RN, Byron PR, Farr SY (eds). Re-
spiratory Drug Delivery, Vol. VI. USA: Interpharma. Press Inc., 1998;
453–455.
35. Chege JK, Chrystyn H. The relative bioavailability of salbutamol to
the lung using urinary excretion following inhalation from a novel
dry powder inhaler: the effect of inhalation rate and formulation.
Respir Med 2000; 94: 51–56.
36. Hill M, Vaughan L, Doovich M. Dose targeting for dry powder
inhalers. In: Dalby RN, Byron PR, Farr SY (eds). Respiratory Drug
Delivery, Vol. V. USA: Interpharma. Press Inc. 1996; 197–208.
37. Warren S, Taylor G, Godfrey C, Cote G, Hill M. Gamma
scintigraphy evaluation of beclomethasone dipropionate (BDP)
from the Spiross Dry Powder Inhaler. J Aerosol Med 1999;
12: A117.
38. Clark AR, Hollingworth AM. The relationship between powder
inhaler resistance and peak inspiratory conditions in healthy
volunteers F implications for in-vitro testing. J Aerosol Med 1993;
6: 99–106.
39. Richards R, Saunders M. Need for a comparative
performance standard for dry powder inhalers. Thorax 1993;
48: 1186–1187.
40. Tarsin W. Assi K, Corrado OJ, Chrystyn H. Measurement of
patient inhalation rates for different dry powder inhalers (DPIs)
using the In-Check Dial Thorax 2000; 55 (Suppl. 3): A63.
41. Tarsin W, Corrado OJ, Brownlee. K, Kanthapillai P, Pearson S,
Chetcuti P, Chrystyn H. Inter-individual variability of peak inhaltion
rates through different inhalers by asthmatic children and adults
and those with COPD. Eur Respir J 2001; 18 (Suppl. 33); 133s.
42. Bisgaard H, Klug B, Sumby BS, Burnell, PKP. Fine particle mass
from the Diskus inhaler and Turbuhaler inhaler in children with
asthma. Eur Respir J 1998; 11: 1111–1115.
43. Bisgaard H, Pedersen S, Nikander K. Use of budesonide
Turbuhalers in young children suspected of asthma. Eur Respir J
1994; 7: 740–742.
44. Hawksworth GM, James L, Chrystyn H. Characterisation of the
inspiratory manoeuvre when asthmatics inhale through a Turbu-
haler pre and post counselling in a Community Pharmacy. Respir
Med 2002; 94: 501–504.
45. Malmstrom K, Sorva R, Silvasti M. Application and effficacy of the
multidose powder inhaler, Easyhalers, in children with asthma.
Pediatr Allergy Immunol 1999; 10: 66–70.
46. Tarsin W. Hawksworth GM Chrystyn H. The intra-individual
variability of inhalation rates through two different dry powder
inhalers. Thorax 2000; 55 (Suppl. 3): A61.
INHALATIONRATEANDDPI 18747. Andersen PB, Stahl E, Hansen NCG. Terbutaline via Turbuhalers
is effective in reversing methacholine-induced bronchoconstric-
tion. J Chem Res 1998, 1: 49–54.
48. Pearce L. The measurement of inspiratory flow in clinical practice.
Drug Delivery to the Lungs, Vol. XI. The Aerosol Society, In: The
Aerosol Society (ed) Bristol, December 2000: 102–104.
49. Nsour W, Alldred A, Corrado OJ, Chrystyn H. Measurement of
peak inspiration rates with an In-Check meter to identify an
elderly patient’s ability to use a Turbuhaler. Respir Med 2001; 95:
965–968.
50. Brajnik UA, Sakharova GM, Makrestskaja ON Belevsky AS,
Chuchalin AG. The role of inspiratory flow measurement in a
choosing suitable inhaler device in asthmatics patients. Eur Resp J
2000; 16 (Suppl. 31): 316s.
51. Emeryk A, Bartkowiak-Emeryk M, Kokot I. Assessment of
inspiratory flow rate (PIFR) is advisable before choosing a dry
powder inhaler for treatment of asthmatic children. Eur Resp J
2000; 10 (Suppl. 31): 540s.
52. Amirav J, Newhouse MT. Measurement of PIF with the In-Check
Dial device to simulate low resistance (Diskus) and high resistance(Turbuhaler) DPIs in children with asthma. Eur Resp J 2000;
540s:P540s.
53. www.Clement-clarke.com/inspiratory/In-check
54. de Boer AH, Winter HMI, Lerk CF. Inhalation characteristics and
their effects on in vitro drug delivery from dry powder inhalers.
Part 1. Inhalation characteristics, work of breathing and volun-
teer’s preference in dependence of the inhaler resistance. Int J
Pharm 1996; 130: 231–244.
55. Everard ML, Devadason SG, Le Soeuf PN. Flow early in the
inspiratory manoeuvre affects the aerosol particle size distribution
from a Turbuhaler. Respir Med 1997; 91: 624–628.
56. Broders MEAC, Molema J, Vermue NA, Folgering HThM. Peak
inspiratory flow rate and slope of inhalation profiles in dry powder
inhalers. Eur Respir J 2001; 18: 78–783.
57. Farr SJ, Rowe AM, Rubsamen R, Taylor G. Aerosol deposition in
the human lung following administration from a microprocessor-
controlled pressurized metered-dose inhaler. Thorax 1995; 50:
639–644.
